Critical Contrast: Taylor Wimpey (OTCMKTS:TWODY) and Zealand Pharma A/S (OTCMKTS:ZLDPF)

Zealand Pharma A/S (OTCMKTS:ZLDPF) and Taylor Wimpey (OTCMKTS:TWODY) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Zealand Pharma A/S and Taylor Wimpey, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	0	2	0	3.00
Taylor Wimpey	0	0	0	0	N/A

Volatility and Risk

Zealand Pharma A/S has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Taylor Wimpey has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Profitability

This table compares Zealand Pharma A/S and Taylor Wimpey’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	-213.77%	-36.96%	-30.10%
Taylor Wimpey	N/A	N/A	N/A

Earnings & Valuation

This table compares Zealand Pharma A/S and Taylor Wimpey’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$49.75 million	94.01	-$102.18 million	($1.82)	-49.89
Taylor Wimpey	$4.37 billion	1.49	$433.99 million	N/A	N/A

Taylor Wimpey has higher revenue and earnings than Zealand Pharma A/S.

Summary

Taylor Wimpey beats Zealand Pharma A/S on 6 of the 8 factors compared between the two stocks.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About Taylor Wimpey

Taylor Wimpey plc operates as a homebuilder in the United Kingdom and Spain. It builds and delivers various homes and communities. Taylor Wimpey plc was incorporated in 1935 and is based in High Wycombe, the United Kingdom.